UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence

Leukemia, 2017-04, Vol.31 (4), p.1015-1016

Baccarani, M

2017

Volltextzugriff (PDF)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Leukemia, 2016-08, Vol.30 (8), p.1648-1671

2016

Volltextzugriff (PDF)

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

Leukemia, 2016-01, Vol.30 (1), p.48-56

2016

Volltextzugriff (PDF)

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Leukemia, 2015-06, Vol.29 (6), p.1336-1343

2015

Volltextzugriff (PDF)

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Blood, 2006-09, Vol.108 (6), p.1809-1820

2006

Volltextzugriff (PDF)

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Leukemia, 2017-03, Vol.31 (3), p.593-601

2017

Volltextzugriff (PDF)

Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients

Leukemia, 2007-02, Vol.21 (2), p.340-350

2007

Volltextzugriff (PDF)

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

Leukemia, 2013-01, Vol.27 (1), p.107-112

2013

Volltextzugriff (PDF)

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

Leukemia, 2015-09, Vol.29 (9), p.1823-1831

2015

Volltextzugriff (PDF)

Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years

Haematologica (Roma), 2013-06, Vol.98 (6), p.875-880

2013

Volltextzugriff (PDF)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

Leukemia, 2016-01, Vol.30 (1), p.57-64

2016

Volltextzugriff (PDF)

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2010-05, Vol.21 (suppl-5), p.v165-v167

2010

Volltextzugriff (PDF)

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2012-10, Vol.23 Suppl 7, p.vii72-vii77

2012

Volltextzugriff (PDF)

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

British journal of cancer, 2012-09, Vol.107 (6), p.904-909

2012

Volltextzugriff (PDF)

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome

Annals of oncology, 2010-04, Vol.21 (4), p.860-863

2010

Volltextzugriff (PDF)

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Leukemia, 2010-07, Vol.24 (7), p.1299-1301

2010

Volltextzugriff (PDF)

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis

Leukemia, 2015-06, Vol.29 (6), p.1344-1349

2015

Volltextzugriff (PDF)

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

Leukemia, 2013-07, Vol.27 (7), p.1511-1519

2013

Volltextzugriff (PDF)

Reply to Constance et al

Leukemia, 2017-03, Vol.31 (3), p.772-773

2017

Volltextzugriff (PDF)

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

Bone marrow transplantation (Basingstoke), 2011-03, Vol.46 (3), p.356-363

2011

Volltextzugriff (PDF)

Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of oncology, 2009-05, Vol.20 (suppl-4), p.iv105-iv107

2009

Volltextzugriff (PDF)

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

Haematologica (Roma), 2016-10, Vol.101 (10), p.1200-1207

2016

Volltextzugriff (PDF)

Monitoring treatment of chronic myeloid leukemia

Haematologica (Roma), 2008-02, Vol.93 (2), p.161-169

2008

Volltextzugriff (PDF)

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

Leukemia, 2009-09, Vol.23 (9), p.1679-1686

2009

Volltextzugriff (PDF)

1 – 25 von 1.313

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.093)
Mit Volltextzugriff
(1.010)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(785)
Humans
(689)
Life Sciences & Biomedicine
(624)
Male
(422)
Adult
(410)
Female
(397)
Middle Aged
(396)
Hematology
(391)
Biological And Medical Sciences
(316)
Medical Sciences
(304)
Aged
(265)
Oncology
(197)
Adolescent
(162)
Technology
(158)
Engineering
(151)
Engineering, Electrical & Electronic
(150)
Hematologic And Hematopoietic Diseases
(141)
Treatment Outcome
(141)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(127)
Physics
(120)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

Reply to Constance et al

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

Monitoring treatment of chronic myeloid leukemia

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

Suchergebnisse filtern